The Recall Desk

Manufacturer

Harbin Jixianglong Biotech Co., Ltd.

2 recalls in our database name Harbin Jixianglong Biotech Co., Ltd. as the manufacturing or recalling firm.

What the numbers show

Total
2
Critical
0
Severe
0
Most recent
2026-03-11

Of the 2 recalls from Harbin Jixianglong Biotech Co., Ltd. we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 0 (0%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

1–2 of 2

  • ModerateFDA (Drugs)·D-0380-2026·2026-03-11

    Semaglutide compounding ingredient recalled over incomplete process and endotoxin validation

    Harbin Jixianglong Biotech is recalling Semaglutide for prescription compounding use because process validation and bacterial endotoxin method validation were not completed before distribution.

    Product
    Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road,
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0379-2026·2026-03-11

    Semaglutide compounding ingredient lot recalled over incomplete validation before distribution

    Harbin Jixianglong Biotech is recalling a further lot of Semaglutide for prescription compounding because process validation and bacterial endotoxin method validation were not completed before distribution.

    Product
    Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street,
    Category
    Drug
    Distribution
    Distributed nationwide